



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

Sotatercept

Cat. No.:	HY-P99590
CAS No.:	1001080-50-7
Target:	TGF- β Receptor
Pathway:	TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions ^{[1][2][3][4][5]} .
IC ₅₀ & Target	ACVR2A
In Vitro	Sotatercept (100 μ g/mL) down-regulates the expression of VEGF, oncostatin-M (OSM), IL-6, BMP-2, MMP-1 and MMP13 secreted by SCs ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Humbert M, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. *N Engl J Med*. 2021 Apr 1;384(13):1204-1215.
- [2]. Raje N, et al. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. *Curr Opin Mol Ther*. 2010 Oct;12(5):586-97.
- [3]. Abdulkadyrov KM, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. *Br J Haematol*. 2014 Jun;165(6):814-23.
- [4]. Sherman ML, et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. *J Clin Pharmacol*. 2013 Nov;53(11):1121-30.
- [5]. Iancu-Rubin C, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. *Exp Hematol*. 2013 Feb;41(2):155-166.e17.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA